OARSI-FDA initiative: Defining the disease state of osteoarthritis

Nancy E Lane, K. Brandt, G. Hawker, E. Peeva, E. Schreyer, W. Tsuji, M. C. Hochberg

Research output: Contribution to journalArticle

165 Citations (Scopus)

Abstract

Objective: To respond to a pre-specified set of questions posed by the United States Food and Drug Administration (FDA) on defining the disease state to inform the clinical development of drugs, biological products, and medical devices for the prevention and treatment of osteoarthritis (OA). Methods: An Osteoarthritis Research Society International (OARSI) Disease State working group was established, comprised of representatives from academia and industry. The Working Group met in person and by teleconference on several occasions from the Spring of 2008 through the Autumn of 2009 to develop consensus-based, evidence-informed responses to these questions. A report was presented at a public forum in December 2009 and accepted by the OARSI Board of Directors in the Summer of 2010. Results: An operational definition of OA was developed incorporating current understanding of the condition. The structural changes that characterize OA at the joint level were distinguished from the patients' experience of OA as the 'disease' and 'illness', respectively. Recommendations were made regarding the evaluation of both in future OA clinical trials. The current poor understanding of the phenotypes that characterize OA was identified as an important area for future research. Conclusions: The design and conduct of clinical trials for new OA treatments should address the heterogeneity of the disease, treatment-associated structural changes in target joints and patient-reported outcomes.

Original languageEnglish (US)
Pages (from-to)478-482
Number of pages5
JournalOsteoarthritis and Cartilage
Volume19
Issue number5
DOIs
StatePublished - May 2011

Fingerprint

United States Food and Drug Administration
Osteoarthritis
Research
Joints
Clinical Trials
Telecommunications
Biological Products
Industry
Therapeutics
Phenotype
Equipment and Supplies
Pharmaceutical Preparations

Keywords

  • Biomarker
  • Clinical trial design
  • MRI
  • OA phenotype
  • Patient-reported outcome

ASJC Scopus subject areas

  • Biomedical Engineering
  • Orthopedics and Sports Medicine
  • Rheumatology

Cite this

Lane, N. E., Brandt, K., Hawker, G., Peeva, E., Schreyer, E., Tsuji, W., & Hochberg, M. C. (2011). OARSI-FDA initiative: Defining the disease state of osteoarthritis. Osteoarthritis and Cartilage, 19(5), 478-482. https://doi.org/10.1016/j.joca.2010.09.013

OARSI-FDA initiative : Defining the disease state of osteoarthritis. / Lane, Nancy E; Brandt, K.; Hawker, G.; Peeva, E.; Schreyer, E.; Tsuji, W.; Hochberg, M. C.

In: Osteoarthritis and Cartilage, Vol. 19, No. 5, 05.2011, p. 478-482.

Research output: Contribution to journalArticle

Lane, NE, Brandt, K, Hawker, G, Peeva, E, Schreyer, E, Tsuji, W & Hochberg, MC 2011, 'OARSI-FDA initiative: Defining the disease state of osteoarthritis', Osteoarthritis and Cartilage, vol. 19, no. 5, pp. 478-482. https://doi.org/10.1016/j.joca.2010.09.013
Lane, Nancy E ; Brandt, K. ; Hawker, G. ; Peeva, E. ; Schreyer, E. ; Tsuji, W. ; Hochberg, M. C. / OARSI-FDA initiative : Defining the disease state of osteoarthritis. In: Osteoarthritis and Cartilage. 2011 ; Vol. 19, No. 5. pp. 478-482.
@article{a3878f3693e04ab29a23efbb07f5cba2,
title = "OARSI-FDA initiative: Defining the disease state of osteoarthritis",
abstract = "Objective: To respond to a pre-specified set of questions posed by the United States Food and Drug Administration (FDA) on defining the disease state to inform the clinical development of drugs, biological products, and medical devices for the prevention and treatment of osteoarthritis (OA). Methods: An Osteoarthritis Research Society International (OARSI) Disease State working group was established, comprised of representatives from academia and industry. The Working Group met in person and by teleconference on several occasions from the Spring of 2008 through the Autumn of 2009 to develop consensus-based, evidence-informed responses to these questions. A report was presented at a public forum in December 2009 and accepted by the OARSI Board of Directors in the Summer of 2010. Results: An operational definition of OA was developed incorporating current understanding of the condition. The structural changes that characterize OA at the joint level were distinguished from the patients' experience of OA as the 'disease' and 'illness', respectively. Recommendations were made regarding the evaluation of both in future OA clinical trials. The current poor understanding of the phenotypes that characterize OA was identified as an important area for future research. Conclusions: The design and conduct of clinical trials for new OA treatments should address the heterogeneity of the disease, treatment-associated structural changes in target joints and patient-reported outcomes.",
keywords = "Biomarker, Clinical trial design, MRI, OA phenotype, Patient-reported outcome",
author = "Lane, {Nancy E} and K. Brandt and G. Hawker and E. Peeva and E. Schreyer and W. Tsuji and Hochberg, {M. C.}",
year = "2011",
month = "5",
doi = "10.1016/j.joca.2010.09.013",
language = "English (US)",
volume = "19",
pages = "478--482",
journal = "Osteoarthritis and Cartilage",
issn = "1063-4584",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - OARSI-FDA initiative

T2 - Defining the disease state of osteoarthritis

AU - Lane, Nancy E

AU - Brandt, K.

AU - Hawker, G.

AU - Peeva, E.

AU - Schreyer, E.

AU - Tsuji, W.

AU - Hochberg, M. C.

PY - 2011/5

Y1 - 2011/5

N2 - Objective: To respond to a pre-specified set of questions posed by the United States Food and Drug Administration (FDA) on defining the disease state to inform the clinical development of drugs, biological products, and medical devices for the prevention and treatment of osteoarthritis (OA). Methods: An Osteoarthritis Research Society International (OARSI) Disease State working group was established, comprised of representatives from academia and industry. The Working Group met in person and by teleconference on several occasions from the Spring of 2008 through the Autumn of 2009 to develop consensus-based, evidence-informed responses to these questions. A report was presented at a public forum in December 2009 and accepted by the OARSI Board of Directors in the Summer of 2010. Results: An operational definition of OA was developed incorporating current understanding of the condition. The structural changes that characterize OA at the joint level were distinguished from the patients' experience of OA as the 'disease' and 'illness', respectively. Recommendations were made regarding the evaluation of both in future OA clinical trials. The current poor understanding of the phenotypes that characterize OA was identified as an important area for future research. Conclusions: The design and conduct of clinical trials for new OA treatments should address the heterogeneity of the disease, treatment-associated structural changes in target joints and patient-reported outcomes.

AB - Objective: To respond to a pre-specified set of questions posed by the United States Food and Drug Administration (FDA) on defining the disease state to inform the clinical development of drugs, biological products, and medical devices for the prevention and treatment of osteoarthritis (OA). Methods: An Osteoarthritis Research Society International (OARSI) Disease State working group was established, comprised of representatives from academia and industry. The Working Group met in person and by teleconference on several occasions from the Spring of 2008 through the Autumn of 2009 to develop consensus-based, evidence-informed responses to these questions. A report was presented at a public forum in December 2009 and accepted by the OARSI Board of Directors in the Summer of 2010. Results: An operational definition of OA was developed incorporating current understanding of the condition. The structural changes that characterize OA at the joint level were distinguished from the patients' experience of OA as the 'disease' and 'illness', respectively. Recommendations were made regarding the evaluation of both in future OA clinical trials. The current poor understanding of the phenotypes that characterize OA was identified as an important area for future research. Conclusions: The design and conduct of clinical trials for new OA treatments should address the heterogeneity of the disease, treatment-associated structural changes in target joints and patient-reported outcomes.

KW - Biomarker

KW - Clinical trial design

KW - MRI

KW - OA phenotype

KW - Patient-reported outcome

UR - http://www.scopus.com/inward/record.url?scp=79955875528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955875528&partnerID=8YFLogxK

U2 - 10.1016/j.joca.2010.09.013

DO - 10.1016/j.joca.2010.09.013

M3 - Article

C2 - 21396464

AN - SCOPUS:79955875528

VL - 19

SP - 478

EP - 482

JO - Osteoarthritis and Cartilage

JF - Osteoarthritis and Cartilage

SN - 1063-4584

IS - 5

ER -